Category Archives: Multaq

Featured Stories
Death in Those Taking Bactrim with ACE Inhibitors or ARBs

Sudden Death in Those Taking Bactrim Along with ACE Inhibitors or ARBs

Association between sudden death in those given Bactrim while already taking renin-angiotensin system blockers angiotensin receptor blockers (ARBs), heart medications.

Read More

FDA Advisory Panel Wrestling with Metal-on-Metal Hip Replacement Safety

An advisory panel for the U.S. Food & Drug Administration (FDA) began a highly-anticipated meeting yesterday to discuss the safety of metal-on-metal hip implants. Among other things, the panel of outside experts is being asked to make recommendations regarding the best practices for monitoring patients with metal-on-metal hip replacements. ...

Read More

New York City Council Calls for Zadroga Act to be Renewed

New York City Council Calls for Zadroga Act to be Renewed

New York City Council members are calling for the Zadroga Act, which provides compensation and medical treatment to 9/11 victims, to be renewed. According to press release issued Jan. 7, a resolution was introduced by Council Member Margaret Chin, Council Speaker Melissa Mark-Viverito and Council Members Paul Vallone and I. ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

Older Patients Face Heart Attack Risk Following Surgery

Older Hip Implant, Knee Replacement Patients Face Heart Attack Risk Following Surgery

An emerging report reveals that older hip implant and knee replacement patients face increased heart attack risks following surgery. The risk for acute myocardial infarction (AMI) was seen in the first two weeks after these surgical procedures.

Read More

Actos Bladder Cancer Lawsuit Filed by West Virginia Resident

Actos (pioglitazone) continues to be named in lawsuits alleging long-term use of the type 2 diabetes drug caused patients to develop bladder cancer. Just last week, the national law firm of Parker Waichman LLP filed suit against Takeda Pharmaceuticals on behalf of a West Virginia man who developed bladder cancer ...

Read More

Lawsuits over DePuy ASR Metal-on-Metal Hip Implants Continue to Mount

DePuy Orthopaedics and its parent, Johnson & Johnson, continue to be hit with lawsuits over recalled metal-on-metal DePuy ASR hip implants. Just yesterday, the national law firm of Parker Waichman LLP announced it had filed yet another DePuy ASR hip implant lawsuit, this time on behalf of a Virginia resident ...

Read More

Conspiracy Claims in Talcum Powder Case Survive Motion to Dismiss

Conspiracy Claims in Talcum Powder Case Survive Motion to Dismiss

E. District of Missouri denied motion to dismiss conspiracy claims. Lawsuit alleges the defendants conspired to misrepresent true dangers with use of talcum powder.

Read More

Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Health Canada has become the most recent national drug regulator to issue a warning about Actos and bladder cancer. Last month, the agency warned that interim results from a 10-year-study indicated that patients taking Actos for more than a year faced an increased risk of bladder cancer. Health Canada also ...

Read More

Bronx Teenager Killed in Hit-and-Run, Second Teen Injured

A Port Jefferson Station man was killed on Wednesday in a single-vehicle crash on the Northern State Pkwy in Dix Hills west of Exit 42. He was driving a Nissan Altima.

Read More

Middle-aged Dronedarone Users Have Higher Risk of Hospitalization

Middle-aged Dronedarone Users Have Higher Risk

New study results reveal that patients age 61 and younger treated with the heart rhythm drug dronedarone (Multaq) have a higher risk for hospitalization than those with treated other anti-arrhythmic drugs. The study, published in Circulation: Cardiovascular Quality and Outcomes, … Continue reading

Posted in Health Concerns, Multaq, Pharmaceuticals | Tagged , , , , |

Multaq Patients Had Double Death Risk in Halted Trial

A study has found that patients taking < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq to control serious, permanent atrial fibrillation, may face a doubled risk of death. Such Multaq patients also face a much higher risk of suffering a heart attack and stroke, according to … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Side Effect Concerns Prompt Restrictions in Europe

Use of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, the Sanofi-Aventis heart drug that has been linked to heart, liver and lung problems, has been restricted by regulators in Europe. According to a report from The Wall Street Journal, a committee of the European Medicines … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Faces FDA Scrutiny As Safety Concerns Mount

The U.S. Food & Drug Administration (FDA) said yesterday that it is continuing to review the safety of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, as more and more specialists report they are no longer prescribing the drug. Multaq has been linked to a number … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Maker Issues Formal Alert for Halted Study

Sanofi-Aventis has formally alerted doctors that a clinical trial involving < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) was halted because patients in the study’s Multaq group were dying at more than twice the rate of that of patients taking placebo. “Healthcare professionals are advised … Continue reading

Posted in Multaq, Pharmaceuticals |

Canada Reviewing Multaq Over Heart Worries

Add Canada to the list of countries taking a deeper look into prescription medication, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). Health Canada, said CTV News, is reviewing the drug’s safety. Multaq is already approved to treat temporary Atrial Fibrillation (AF), or abnormal heart … Continue reading

Posted in Multaq |

New Multaq Alert Issued by FDA

Following an expanded European Medicines Agency (EMA) probe, the U.S. Food and Drug Administration (FDA), as expected, announced that it will be reviewing information from a < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq clinical trial that was stopped over higher-than-expected adverse heart reactions in trial … Continue reading

Posted in Multaq |

Multaq Heart Side Effects Under Review in Europe

Sanofi is facing an expansion of an ongoing review of its atrial fibrillation (AF) treatment, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). The European Medicines Agency (EMA) found that a study revealed possible heart risks in patients using the drug, said FiercePharma. The Agency … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Trial Halted Due to Significant Increase in Heart Problems

A clinical trial for < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) has ended early after a significant number of heart-related side effects were seen in the study. The trial, known as the PALLAS study, was testing Multaq’s as a treatment for permanent atrial fibrillation. … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Patients Should Undergo Liver Function Tests

European regulators recently warned that < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (donedarone) could put patients at risk for severe liver injuries. The European Medicines Agency (EMA) is now recommending that doctors perform liver function tests before treating atrial fibrillation patients with Multaq. The European … Continue reading

Posted in Multaq, Pharmaceuticals | Tagged , , , , |

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.